With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test
May 10, 2011
With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test
In the company's first-quarter earnings call, Sequenom CEO Harry Hixson said he believes that other companies developing similar sequencing-based trisomy 21 tests are infringing Sequenom's intellectual property.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sequenom Says Competitors Will Have to License IP for Noninvasive T21 Detection Tests
July 27, 2011 / Clinical Sequencing News - As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012 / Clinical Sequencing News - Verinata Licenses Quake Patent, Setting Stage for IP Tussle with Sequenom
September 7, 2011 / Clinical Sequencing News - Building on Trisomy 21 Test, Hong Kong Team Develops Method to Detect T13 and T18
July 6, 2011 / Clinical Sequencing News - Sequenom Runs More Than 13K T21 Tests in Q2; Plans to Expand Capacity in US and Overseas
August 1, 2012 / Clinical Sequencing News